259 related articles for article (PubMed ID: 30172479)
1. Does MMR status in endometrial cancer influence response to adjuvant therapy?
Kim SR; Pina A; Albert A; McAlpine J; Wolber R; Blake Gilks C; Kwon JS
Gynecol Oncol; 2018 Oct; 151(1):76-81. PubMed ID: 30172479
[TBL] [Abstract][Full Text] [Related]
2. Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers.
Kim SR; Pina A; Albert A; McAlpine JN; Wolber R; Gilks B; Carey MS; Kwon JS
Int J Gynecol Cancer; 2020 Jun; 30(6):783-788. PubMed ID: 32354793
[TBL] [Abstract][Full Text] [Related]
3. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.
Reijnen C; Küsters-Vandevelde HVN; Prinsen CF; Massuger LFAG; Snijders MPML; Kommoss S; Brucker SY; Kwon JS; McAlpine JN; Pijnenborg JMA
Gynecol Oncol; 2019 Jul; 154(1):124-130. PubMed ID: 31103324
[TBL] [Abstract][Full Text] [Related]
4. Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer.
Resnick KE; Frankel WL; Morrison CD; Fowler JM; Copeland LJ; Stephens J; Kim KH; Cohn DE
Gynecol Oncol; 2010 May; 117(2):234-8. PubMed ID: 20153885
[TBL] [Abstract][Full Text] [Related]
5. Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study.
Pina A; Wolber R; McAlpine JN; Gilks B; Kwon JS
Int J Gynecol Cancer; 2018 Oct; 28(8):1624-1630. PubMed ID: 30095707
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
Li JY; Park HS; Huang GS; Young MR; Ratner E; Santin A; Damast S
Gynecol Oncol; 2021 Dec; 163(3):557-562. PubMed ID: 34602287
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM
Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272
[TBL] [Abstract][Full Text] [Related]
9. Definitive radiotherapy for vaginal recurrence of early-stage endometrial cancer: survival outcomes and effect of mismatch repair status.
Alban G; Cheng T; Adleman J; Buzurovic I; Pretz J; Singer L; King M; Lee L
Int J Gynecol Cancer; 2021 Jul; 31(7):1007-1013. PubMed ID: 33858956
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma.
Yoneoka Y; Yoshida H; Ishikawa M; Shimizu H; Uehara T; Murakami T; Kato T
J Gynecol Oncol; 2019 Jan; 30(1):e7. PubMed ID: 30479091
[TBL] [Abstract][Full Text] [Related]
11. Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer.
Loukovaara M; Pasanen A; Bützow R
Cancer Med; 2021 Feb; 10(3):1034-1042. PubMed ID: 33449452
[TBL] [Abstract][Full Text] [Related]
12. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
13. Survival Analysis of Cancer Patients With FIGO Stage IIIA Endometrial Cancer.
Lum MM; Belnap TW; Frandsen J; Brown AP; Sause WT; Soisson AP; Dodson MK; Werner T; Gaffney DK
Am J Clin Oncol; 2015 Jun; 38(3):283-8. PubMed ID: 23774072
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma.
Yoon MS; Huh SJ; Kim HJ; Kim YS; Kim YB; Kim JY; Lee JH; Kim HJ; Cha J; Kim JH; Kim J; Yoon WS; Choi JH; Chun M; Choi Y; Lee KK; Kim M; Jeong JU; Chang SK; Park W
Cancer Res Treat; 2016 Jul; 48(3):1074-83. PubMed ID: 26511800
[TBL] [Abstract][Full Text] [Related]
15. Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma.
Sozen H; Çiftçi R; Vatansever D; Topuz S; Iyibozkurt AC; Bozbey HU; Yaşa C; Çali H; Yavuz E; Kucucuk S; Aydiner A; Salihoglu Y
Aust N Z J Obstet Gynaecol; 2016 Apr; 56(2):199-206. PubMed ID: 26890292
[TBL] [Abstract][Full Text] [Related]
16. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
[TBL] [Abstract][Full Text] [Related]
17. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
[TBL] [Abstract][Full Text] [Related]
18. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
19. Mismatch repair status and surgical approach in apparent early-stage endometrial cancer.
Morton R; Webb PM; Na R; Obermair A; Farrell R
Int J Gynecol Cancer; 2024 Apr; 34(4):535-543. PubMed ID: 38431289
[TBL] [Abstract][Full Text] [Related]
20. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.
Secord AA; Havrilesky LJ; O'Malley DM; Bae-Jump V; Fleming ND; Broadwater G; Cohn DE; Gehrig PA
Gynecol Oncol; 2009 Sep; 114(3):442-7. PubMed ID: 19560193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
